Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K042946
    Manufacturer
    Date Cleared
    2004-12-07

    (42 days)

    Product Code
    Regulation Number
    866.1645
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The VITEK® Gram Positive Susceptibility Test is intended to be used with the VITEK® System for automated quantitative or qualitative susceptibility testing of isolated colonies of the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae. VITEK® Gram Positive Rifampin is designed for antimicrobial susceptibility testing of Staphylococcus aureus and Staphylococcus epidermidis. VITEK Gram Positive Rifampin is intended for use with the VITEK System as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.

    Device Description

    VITEK® Gram Positive Rifampin is designed for antimicrobial susceptibility testing of Staphyloccocus aureus and Staphylococcus epidermidis. It is intended for use with the VITEK® System as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. The antimicrobial presented in VITEK GPS Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK GPS Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology. After the card is inoculated with a standardized organism suspension, it is placed in the Reader/Incubator of the VITEK System. Organism growth inside the card is optically monitored throughout the 6-15 hour incubation cycle. MIC results are automatically calculated once a predetermined growth threshold is reached, and a report is generated that contains the MIC result and the interpretive category result.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study details for the VITEK® Gram Positive Rifampin device, based on the provided text:

    Acceptance Criteria and Device Performance

    Acceptance CriteriaReported Device Performance
    Overall Category Agreement compared to NCCLS reference agar dilution method98.9%
    ReproducibilityAcceptable results
    Quality ControlAcceptable results

    Note: The specific numerical acceptance thresholds for Reproducibility and Quality Control are not detailed in the provided text, only that the results were "acceptable." The overall Category Agreement target is implied by the reported performance being considered acceptable against the guidance document.

    Study Details

    2. Sample Size Used for the Test Set and Data Provenance:

    • Test Set Description: "fresh and stock clinical isolates" and "challenge strains."
    • Sample Size: Not explicitly stated in the provided text.
    • Data Provenance: Not explicitly stated (e.g., country of origin). The study was referred to as an "external evaluation," suggesting it was conducted outside of bioMérieux's internal labs.
    • Retrospective/Prospective: Not explicitly stated, though "fresh clinical isolates" suggests a prospective component.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:

    • Not applicable/Not mentioned. The ground truth was established by a reference method (NCCLS agar dilution method), not by expert opinion.

    4. Adjudication Method for the Test Set:

    • Not applicable. The ground truth was established by a reference method, not through expert adjudication.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

    • No, a MRMC comparative effectiveness study was not done. This study focuses on the performance of the automated system against a reference method, not on human reader performance with or without AI assistance.

    6. Standalone Performance Study:

    • Yes, a standalone study was done. The entire evaluation describes the performance of the VITEK® Gram Positive Rifampin (an algorithm-driven automated system) directly compared to the NCCLS reference agar dilution method. This is a standalone performance assessment of the device.

    7. Type of Ground Truth Used:

    • Reference Method: The NCCLS reference agar dilution method.

    8. Sample Size for the Training Set:

    • Not explicitly mentioned. The text focuses on the "external evaluation" which describes the test set. There's no information provided about a separate training set.

    9. How the Ground Truth for the Training Set Was Established:

    • Not applicable/Not mentioned, as details about a training set are not provided. If a training set was used, it would likely also be established using a reference method like the NCCLS agar dilution method, similar to the test set.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1